ATC Group: A16AB26 Eladocagene exuparvovec

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A16AB26 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A16 Other alimentary tract and metabolism products
3 A16A Other alimentary tract and metabolism products
4 A16AB Enzymes
5 A16AB26

Active ingredients in A16AB26

Active Ingredient Description
Eladocagene exuparvovec

Eladocagene exuparvovec is a gene therapy based on recombinant AAV2 vector containing the human cDNA for the DDC gene. After infusion into the putamen, the product results in the expression of the AADC enzyme and subsequent production of dopamine, and consequently, development of motor function in treated AADC-deficient patients.

Medicines in this ATC group

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.